E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
X-Linked Retinitis Pigmentosa caused by mutations in the RPGR gene |
|
E.1.1.1 | Medical condition in easily understood language |
Progressive reduction in vision, starting with night blindness and progressing to visual field constriction, caused by mutations on Chromosome X (RPGR gene). |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Eye Diseases [C11] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10038914 |
E.1.2 | Term | Retinitis pigmentosa |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary research objective is to assess the longer term safety of AAV5-hRKp.RPGR administered to participants in the RPGR trial, measured by the presence or absence of adverse events, the assessment of visual acuity, and loss of light perception. |
|
E.2.2 | Secondary objectives of the trial |
The secondary research objective is to estimate the longer-term efficacy of AAV5-hRKp.RPGR in change after treatment administration in functional vision, visual function and retinal function. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Inclusion in the study will be limited to individuals who meet the following criteria: • Are able to give informed consent or assent, with or without the guidance of their parent/guardian where appropriate • Received AAV5-hRKp.RPGR by sub retinal administration in the prior open-label, Phase I/II, dose escalation study (EudraCT 2016-003967-21) • Are willing to adhere to the protocol and long-term follow-up |
|
E.4 | Principal exclusion criteria |
Individuals will be excluded if they are unwilling or unable to meet with the requirements of the study. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary outcome is safety of subretinal administration of the ATIMP. Safety will be analyzed by review of adverse events. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Timepoints between 6 and 60 months post ATIMP administration in study MGT009 for deferred treatment arm and between 12 and 60 months post ATIMP administration in study MGT009 for immediate treatment arm. |
|
E.5.2 | Secondary end point(s) |
The secondary research objective is to estimate the longer-term efficacy of AAV5 hRKp.RPGR in change after treatment administration in: Functional Vision: - Walk time in Vision-guided mobility assessment (VMA) - Low Luminance Questionnaire (LLQ) domain scores in patient reported outcome
Visual Function: - Best Corrected Visual Acuity (BCVA) by Early Treatment Diabetic Retinopathy Study (ETDRS) chart letter score - Low Luminance Visual Activity (LLVA) by ETDRS chart letter score
Retinal Function: - Mean retinal sensitivity within the central 10 degree visual field excluding scotoma (MRS10) in static perimetry - Responder in Pointwise data in static perimetry within the full visual field - Responder in Pointwise data in static perimetry within the central 30-degree visual field - Mean retinal sensitivity within the full visual field excluding scotoma (MRS90) in static perimetry |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
At 12 (deferred treatment arm only), 18, 24, 36, 48 and 60 months following ATIMP administration in study MGT009. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | Yes |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
Long Term Follow Up Trial |
|
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
Will this trial be conducted at a single site globally?
| Yes |
E.8.4 | Will this trial be conducted at multiple sites globally? | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 8 |
E.8.9.2 | In all countries concerned by the trial months | 3 |
E.8.9.2 | In all countries concerned by the trial days | 31 |